Biovail launches Ralivia in Canada

Ralivia has been shown to produce reductions in pain intensity relative to placebo as early as the first day of treatment, with analgesic efficacy increasing throughout the first four weeks of treatment. Ralivia has also been shown to produce significant improvements in sleep in approximately 60% of patients, including improvements in sleep quality, trouble falling asleep, and awakening by pain at night and in the morning.

Scott Smith, vice-president and general manager of BPC, said: “For patients with chronic pain, Ralivia provides comparable efficacy to non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors without the long-term cardiovascular and gastrointestinal risks associated with their continuous use.”